The recent findings underscore the potential of SGLT-2 inhibitors, especially in combination with glucagon-like peptide-1 receptor agonists (GLP-1), to improve survival outcomes in lung cancer patients with type 2 diabetes (Chen et al., 2025). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.